The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators-A pilot study

Clinical Biochemistry

Volumn 48, Issue 9, 2015, Pages 557-561

  Kucera, Marek ^a   Balaz, David ^a   Kruzliak, Peter ^b,c   Ciccocioppo, Rachele ^d   Oravec, Stanislav ^a   Rodrigo, Luis ^e   Zulli, Anthony ^f   Hirnerova, Eva ^a   Sabaka, Peter ^a   Komornikova, Andrea ^a   Sabo, Jan ^e   Slezak, Peter ^g   Gaspar, Ludovit ^a  

^a UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c P J AFÁRIK UNIVERSITY   (Slovakia)

^d UNIVERSITY OF PAVIA   (Italy)

^e Central University Hospital of Asturias (HUCA)   (Spain)

^f VICTORIA UNIVERSITY   (Australia)

^g Physics and Informatics   (Slovakia)

Author keywords

Atherogenic dyslipidaemia; Atorvastatin; Dense LDL; Mean platelet volume; Red cell distribution width; Small

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; APOA1 PROTEIN, HUMAN; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; ATHEROGENIC INDEX OF PLASMA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CORRELATIONAL STUDY; DRUG EFFECT; DYSLIPOPROTEINEMIA; ERYTHROCYTE PARAMETERS; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; MALE; PILOT STUDY; PRIORITY JOURNAL; RED CELL DISTRIBUTION WIDTH; THROMBOCYTE VOLUME; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ATHEROSCLEROSIS; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; DYSLIPIDEMIAS; MEAN CORPUSCULAR VOLUME; MIDDLE AGED;

AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; ATORVASTATIN CALCIUM; DYSLIPIDEMIAS; ERYTHROCYTE INDICES; FEMALE; HUMANS; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; PILOT PROJECTS;

EID: 84929945116     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.02.010     Document Type: Article

References (43)

1. National Cholesterol Education Program (NCEP), Expert Panel on Detection, Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
2. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 2010, 45:907-914.
3. Ridker P.M., Rifai N., Cook N.R., Bradwin G., Buring J.E. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005, 20:326-333.
4. Superko H.E. Advanced lipoprotein testing and subfractionation are clinically useful. Circulation 2009, 119:2383-2395.
5. Oravec S., Gruber K., Dostal E. Hyper-betalipoproteinemia LDL 1,2: a newly identified nonatherogenic hypercholesterolemia in a group of hypercholesterolaemic subjects. Neuro Endocrinol Lett 2011, 32:322-327.
6. Kwon S.W., Yoon S.J., Kang T.S., Kwon H.M., Kim J.H., Rhee J., et al. Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome. Yonsei Med J 2006, 47:405-414.
7. Shoji T., Hatsuda S., Tsuchikura S., Shinohara K., Kimoto E., Koyama H., et al. Small dense low-density lipoprotein cholesterol concentration and carotis atherosclerosis. Atherosclerosis 2009, 202:582-588.
8. Martin J.F., Trowbridge E.A., Salmon G., Plumb J. The biological significance of platelet volume: its relationship to bleeding time, thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983, 32:443-460.
9. Pizzulli L., Yang A., Martin J.F., Luderttz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J 1998, 19:80-84.
10. Perlstein T.S., Weuve J., Pfeffer M.A., Beckman J.A. Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med 2009, 169:588-594.
11. Ray K.K., Cannon C.P., McCabe C.H., Cairns R., Tonkin A.M., Sacks F.M., et al. PROVE IT-TIMI 22 Investigators (2005) Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005, 46:1405-1410.
12. Bickel C, Rupprecht HJ, Blankenberg S, spinola-Klein C, Rippin G, Hafner G, Lotz J, Prellwitz W, Meyer J; AtheroGene Group Influence of HMGCoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002, 82:25-31.
13. Undas A., Brummel-Ziedins K.E., Potaczek D.P., Stobierska-Dzierzek B., Bryniarski L., Szczeklik A., et al. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28days of therapy. J Thromb Haemost 2006, 11:2397-2404.
14. Akin F., Ayca B., Köse N., Sahin I., Akin M.N., Canbek T.D., et al. Effect of atorvastatin on haematologic parameters in patients with hypercholesterolemia. Angiology 2013, 64:621-625.
15. Varol E., Aksoy F., Bas H.A., Ari H., Ozaydin M. Mean platelet volume is elevated in patients with low high-density lipoprotein cholesterol. Angiology 2014, 65:733-736.
16. Lippi G., Sanchis-Gomar F., Danese E., Montagnana M. Association of red blood cell distribution width with plasma lipids in a general population of unselected outpatients. Kardiol Pol 2013, 71:931-936.
17. Hoefner D.M., Hodel S.D., O'Brien J.F., Branum E.L., Sun D., Meissner I., et al. Development of a rapid quantitative method for LDL subfractionation with use of the quantimetrix lipoprint LDL system. Clin Chem 2001, 47(2):266-274.
18. Briel M., Vale N., Schwartz G.G., de Lemos J.A., Colivicchi F., den Hartog F.R., et al. Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients. Int J Cardiol 2012, 158:93-100.
19. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005, 96:24F-33F.
20. Athyros V.G., Tziomalos K., Florentin M., Karagiannis A., Mikhailidis D.P. Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. Curr Med Res Opin 2010, 26:839-842.
21. Marzilli M. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs 2010, 10(1):3-9.
22. Ma L.P., Nie D.N., Hsu S.X., Yin S.M., Xu L.Z., Nunes J.V. Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia. J Assoc Acad Minor Phys 2002, 13(1):23-26.
23. Luzak B., Rywaniak J., Stanczyk L., Watala C. Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition. Eur J Clin Invest 2012, 42(8):864-872.
24. Kapoor J.R. Platelet activation and atherothrombosis. N Engl J Med 2008, 15:1638-1639.
25. Moscardó A., Vallés J., Latorre Madrid I., Santos M.T. Reduction of platelet cytosolic phospholipase A 2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms. Thromb Res 2013, 131:e154-e159.
26. Chou T.C., Lin Y.F., Wu W.C., Chu K.M. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin. Br J Pharmacol 2008, 153:1281-1287.
27. Lee Y.M., Chen W.F., Chou D.S., Jayakumar T., Hou S.Y., Lee J.J., et al. Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation. J Biomed Sci 2010, 17:45.
28. Bruni F., Pasqui A.L., Pastorelli M., Bova G., Cercignani M., Palazzuoli A., et al. Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects. Clin Appl Thromb Hemost 2005, 11:417-428.
29. Pignatelli P., Carnevale R., Pastori D., Cangemi R., Napoleone L., Bartimoccia S., et al. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation 2012, 126(1):92-103.
30. Takemoto M., Liao Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
31. Davi G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357:2482-2494.
32. Sivri N., Tekin G., Yalta K., Aksoy Y., Senen K., Yetkin E. Statins decrease mean platelet volume irrespective of cholesterol lowering effect. Kardiol Pol 2013, 71:1042-1047.
33. Coban E., Afacan B. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment. Platelets 2008, 19(2):111-114.
34. Yetkin E. Mean platelet volume not so far from being a routine diagnostic and prognostic measurement. Thromb Haemost 2008, 100:3-4.
35. Gaddam V., Li D.Y., Mehta J.L. Anti-thrombotic effects of atorvastatin-an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther 2002, 7:247-253.
36. Evans T.C., Jehle D. The red blood cell distribution width. J Emerg Med 1991, 9:71-74.
37. Anderson J.L., Ronnow B.S., Horne B.D., Carlquist J.F., May H.T., Bair T.L., et al. Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease. Am J Cardiol 2007, 99:169-174.
38. Horne D., Anderson J.L., Muhlstein J.B., Ridker P.M., Paynter N.P. JUPITER trial Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial. Eur J Prev Cardiol 2015, 22:519-526.
39. Kucera M., Oravec S., Hirnerova E., Huckova N., Celecova Z., Gaspar L., et al. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study. Angiology 2014, 65(9):794-799.
40. Horne B.D. The red cell distribution width: what is its value for risk prognostication and for understanding disease pathophysiology?. Cardiology 2011, 119:140-141.
41. Tonelli M., Sacks F., Arnold M., Moye L., Davis B., Pfeffer M., et al. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation 2008, 117(2):163-168.
42. Arai H., Kokubo Y., Watanabe Sawamura T., Ito Y., Minagawa A., Okamura T., et al. Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study. J Atheroscler Thromb 2013, 20:195-203.
43. Bath P.M., Butterworth R.J. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996, 7:157-161.